Recently Befroy and colleagues 1 measured tricarboxylic acid (TCA) cycle flux and anaplerosis in human liver by analyzing 13 C enrichment in the C1 and C5 positions of glutamate during [1-13 C]acetate infusion 1 . The authors concluded that anaplerosis was equal to ~1.4 times TCA cycle flux, and that other methods overestimate this flux 1 . The entry of [1-13 C]acetyl-CoA into the cycle yields [5-13 C]glutamate on each turn of the cycle, but [1-13 C]glutamate appears only on subsequent turns. Anaplerosis, for instance via pyruvate carboxylation, results in the influx of unlabeled oxaloacetate. The subsequent loss of 13 C-oxaloacetate from the cycle to make phosphoenolpyruvate (PEP) decreases the enrichment in glutamate C1 but not glutamate C5. Hence, the steady-state ratio of [1-13 C]glutamate to [5-13 C]glutamate should reflect anaplerosis relative to TCA cycle activity (i.e., citrate synthase flux = 1). PEP formed from decarboxylation of oxaloacetate has at least two fates, either to contribute to gluconeogenesis (GNG) or to regenerate pyruvate via pyruvate kinase (PK). PK, and other pathways (for example, malic enzyme), contribute to a futile pyruvate cycle whereby oxaloacetate → pyruvate → oxaloacetate. The relationship among these variables is simple: GNG = anaplerosis -PK flux. This pathway has been included in virtually all models of hepatic GNG 2-9 . In humans, various values of PK flux relative to citrate synthase (CS) have been reported, varying from 1.5 to 5.8 when determined using a [3-14 C]lactate tracer with radioisotope detection 8 , [3-13 C] lactate tracer with mass isotope detection 3 or [U-13 C]propionate tracer
with nuclear magnetic resonance (NMR) detection 6, 9 . In fact, pyruvate cycling accounted for the majority of anaplerosis in these human studies 3, 6, 8, 9 , yet was excluded from anaplerosis by Befroy et al. 1 This exclusion complicates the analysis considerably because pyruvate cycling in the presence of H 13 CO 3 -, as observed in the in vivo 13 C NMR spectra 1 , regenerates [1-13 C]glutamate. Hence, the steady-state ratio of [1-13 C] glutamate to [5] [6] [7] [8] [9] [10] [11] [12] [13] C]glutamate no longer reflects total anaplerosis. Given the implications, it is worth examining the effect of pyruvate cycling on 13 C in glutamate C1 and C5 using the conditions reported by Befroy et al. 1 13 C labeling in glutamate is a complex function of pyruvate cycling, anaplerosis and enrichment in acetyl-CoA and bicarbonate 4, 10 . Consequently, simulations must be used to explore these interactions 10 . Using published relationships 10 and the conditions reported by Befroy et al. 1 , the ratio of [1-13 C]glutamate to [5] [6] [7] [8] [9] [10] [11] [12] [13] C]glutamate (glutamate 13 C1/ 13 C5) is sensitive to total anaplerosis if 13 CO 2 = 0 and pyruvate cycling = 0, but much less sensitive when 13 CO 2 = 6% (ref. 1) and pyruvate cycling is active [2] [3] [4] [5] [6] [7] [8] [9] (Fig. 1) . The ratio of [1-13 C]glutamate to [5-13 C] glutamate reported by Befroy et al. 1 is indeed consistent with substantial pyruvate cycling (Fig. 1) , as previously described in human liver 3, 6, 8, 9 . However, the presence of pyruvate cycling also means that a fivefold range in anaplerosis is essentially undetectable by the ratio of [1-13 C]glutamate to [5-13 C]glutamate. Thus, this method cannot be used to support the conclusion by Befroy et al. 1 that other methods have overestimated anaplerosis, as the ratio of 13 C-labeled C1 to 13 C-labeled C5 cannot detect total anaplerosis under these conditions (Fig. 1) .
Futile cycles serve a role in the regulation of metabolism. Earlier studies, including those in humans, found that the futile cycle interconverting pyruvate and oxaloacetate is unquestionably active in liver regardless of whether lactate or propionate tracers are used [2] [3] [4] [5] [6] [7] [8] [9] . Thus, it is best to assume that pyruvate cycling is always a feature of liver metabolism and to incorporate this possibility in data analysis. 
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Reprints and permissions information is available online at http://www.nature.com/ reprints/index.html. Figure 1 The effect of pyruvate cycling on the steady-state ratio of [1-13 C]glutamate to [5-13 C]glutamate ( 13 C1/ 13 C5). Data were simulated using tcaSIM. All simulations were conducted using an [1-13 C]acetyl-CoA fractional enrichment of 0.22 and 13 CO 2 fractional enrichment of 0.06, as reported by Befroy et al. 1 Anaplerosis relative to TCA cycle flux (CS) was varied from 1.4, as reported by Befroy et al. 1 , to 8. The 13 C1/ 13 C5 ratio decreases by 40% across this range under the assumption of no pyruvate cycling (for example, PK) activity. The 13 C1/ 13 C5 ratio is unresponsive to anaplerosis when pyruvate cycling is concomitantly active, because the resulting 13 C-labeled pyruvate condenses with 13 CO 2 (i.e., PC) and ultimately regenerates [1-13 C]glutamate. Most notably, the method used by Befroy et al. 1 cannot distinguish low anaplerosis from higher values 9 . 5, 6 . More importantly, simulations demonstrated that pyruvate cycling had no significant impact on our estimates of V ANA and V TCA . Although our analysis indicated that PK flux must be low, owing to uncertainty in establishing an absolute rate of pyruvate cycling we felt that including it in our article would be misleading.
In support of their hypothesis, Burgess et al. 1 applied a steady-state model 7 to simulate the ratio of glutamate C1 to glutamate C5 under a range of PK flux conditions. Unfortunately, their model is not suitable for examining our data because the system was not at isotopic steady state-enrichment of bicarbonate and glutamate C1 continue to increase throughout the 2-h study-and this leads to erroneous interpretations. In contrast, our analysis is based on the kinetics of plasma acetate and hepatic bicarbonate and glutamate 13 C enrichment, where each time point contributes to establishing the metabolic rates that best fit the raw data. Here we demonstrate the effects of pyruvate cycling on the kinetics and magnitude of glutamate C1 enrichment (Fig. 1) ; low rates of V PK clearly fit the experimental data better than the higher values (V PK /V TCA > 3.5) suggested by Burgess et al. 1, 5, 6 .
Low rates of pyruvate cycling are supported by other experimental evidence. We observed minimal labeling at C1 of pyruvate in liver tissue extracts from our studies of rats infused with [1-13 C] acetate 2 , suggesting that PK flux is very low. We have also estimated V (PK + ME) / V (PC + PDH) from the ratio of alanine C2 to glucose C5 enrichment in rat liver during an infusion of [3-13 C]alanine 3, 4 . Hepatic V (PK + ME) in these experiments was estimated to be <27% of V (PC + PDH) , more than an order of magnitude lower than that reported by Sunny et al. 5 . Furthermore, during an infusion of [3-13 C] lactate in humans who had fasted overnight, we observed negligible 13 C labeling of C2 in hepatic alanine and C2 of lactate pools using our in vivo 13 C magnetic resonance spectroscopy technique (Fig. 2) . The shift in 13 C label from the C3 to the C2 position requires an isotopic equilibration that occurs owing to the rapid interconversion of OAA-malate-fumarate followed by the regeneration of pyruvate via V PK . Rapid rates of pyruvate cycling would lead to the appearance of alanine C2 and lactate C2 peaks of similar magnitude to their C3 counterparts, which we did not observe (Fig. 2) . In contrast, we observed substantial 13 C enrichment of hepatic glutamate C2 and glucose C6 owing to anaplerosis and gluconeogenesis, respectively.
Finally, pyruvate cycling and gluconeogenesis from PEP require obligate energy consumption. On the basis of the data from Sunny et al. 5 , where gluconeogenesis is approximately equivalent to TCA flux and pyruvate cycling is ~3.5 times TCA flux, the energy produced by the TCA cycle would be almost entirely consumed by these processes, a situation that is energetically unsustainable.
In conclusion, the rates of pyruvate cycling reported by Burgess et
Befroy et al. reply:
Burgess et al. 1 comment that the modeling approach used in our recent article 2 may have led to an incorrect estimate of hepatic anaplerosis because we did not explicitly include a term for pyruvate cycling. Although we agree that a pyruvate substrate cycle is a feature of hepatic metabolism, we contend that under most conditions, the flux through this cycle is low, relative to the TCA cycle (V TCA ), and therefore does not substantially affect the rates of anaplerosis (V ANA ) that we reported. Furthermore, our measurements of V TCA depend primarily on the kinetics of enrichment of glutamate at C5, which are independent of V ANA and pyruvate cycling via pyruvate kinase (V PK ). Several independent lines of evidence support these conclusions. Hepatic glutamate enrichment during these experiments is a complex function of the enrichments in acetyl-CoA, pyruvate and carbon dioxide, and the metabolic reactions that interact with these substrates, including V TCA , gluconeogenesis from phosphoenolpyruvate and entry of pyruvate-carbon-dioxide through pyruvate carboxylase and malic enzyme. Under fasting conditions, malic enzyme activity is low 3, 4 , therefore pyruvate entry is almost exclusively through pyruvate carboxylase flux (V PC ). V PC incorporates components owing to V ANA and V PK , which we consider to be metabolically distinct processes. Anaplerotic pyruvate entry is required under gluconeogenic conditions to replenish the pool of TCA cycle intermediates that would otherwise be depleted due to the consumption of oxaloacetate (OAA) to form glucose via phosphoenolpyruvate (PEP), whereas pyruvate cycling involves the futile consumption and regeneration of pyruvate. Under this rationale, V PC = [V ANA + V PK ]. Because the total metabolite mass remains constant, V ANA is also equivalent to the gluconeogenic flux from PEP. An earlier version of our model of hepatic metabolism included a discrete term for V PK to account for pyruvate cycling. Probability distribution analysis of Monte Carlo simulations of this model determined that V PK /V TCA was most likely to be <<0.49, with upper bound estimates (the 66th and 95th percentile Figure 1 The effect of pyruvate cycling, expressed as V PK /V TCA , on the kinetics of hepatic [1-13 C]glutamate ( 13 C1-Glu) enrichment during a 2-h infusion of [1-13 C]acetate. Raw data (black diamonds) are reproduced from Befroy et al. 2 . Low rates of V PK clearly fit the experimental data better than the higher values suggested by Burgess et al. 1 . All studies were approved by the Yale Human Investigation Committee, and informed written consent was obtained from all subjects. 
